Iliac Stent Market (2026 - 2033)

Iliac Stent Market Size & Trends

The global iliac stent market size was valued at USD 1.2 billion in 2025 and is projected to grow from USD 1.3 billion in 2026 to USD 2.0 billion by 2033, at a CAGR of 6.5% from 2026 to 2033. The market in North America dominated with a revenue share of 43.8% in 2025. Iliac stents are small mesh tubes used to support narrowed iliac arteries. 

Source: Grand View Research, IR Documents, Primary Interviews, Paid Databases

To learn more about this report, Download Free Sample Report

The growth of the market can be attributed to growing advancements in medical technology, increasing prevalence of peripheral artery diseases, and expanding awareness about minimally invasive procedures as an effective treatment option. According to an article published by the NCBI in March 2022, more than 2 million people in the U.S. undergo a stent procedure yearly. The increasing prevalence of peripheral artery diseases (PAD) is expected to boost the demand for iliac stents. According to the American Heart Association, nearly 8.5 million adults, or 7% of the U.S. population, suffer from PAD. PAD narrows and blocks the arteries in peripheral vascular systems, including iliac arteries, thereby, placement of iliac stents allows to restore blood flow in those arteries. Moreover, aortoiliac occlusive disease (AIOD) is a type of PAD that affects the infrarenal aorta and iliac arteries. Similar to other conditions affecting arteries, AIOD restricts blood circulation to distant organs by restricting blood vessels or causing plaque embolization. Iliac stents are implanted to expand the narrowed or obstructed arteries, thereby reinstating normal blood flow and relieving symptoms linked to AIOD.

To learn more about this report, Download Free Sample Report

In addition, the growing geriatric population across the world is expected to boost the iliac stents market. According to an article by WebMD LLC, the incidence of PAD increases with advancing age, whereby nearly 25% of the U.S. population aged 70 and above is diagnosed with PAD. According to the Population Reference Bureau data, the number of Americans aged 65 is expected to increase from 58 million in 2022 to 82 million in 2050 and is projected to account for nearly 23% of the population in 2050, from 17% in 2022. Moreover, similar growth in the senior population across countries is expected to provide lucrative opportunities for the iliac stents market players.

Market Dynamics

The Iliac Stent market is experiencing steady growth, driven by the increasing prevalence of peripheral artery disease (PAD), atherosclerosis, and other vascular disorders that lead to iliac artery stenosis and occlusions. Iliac stents are widely utilized in endovascular interventions to restore blood flow, manage chronic total occlusions, and treat complex iliac artery lesions, offering a minimally invasive alternative to open surgical bypass procedures. Rising volumes of vascular interventions, coupled with the growing preference for endovascular therapies due to reduced recovery time, lower complication rates, and improved clinical outcomes, are significantly contributing to market growth. In addition, the expanding geriatric population, which is more susceptible to vascular diseases and impaired arterial function, is further accelerating demand for iliac stenting procedures. 

Driver: Advancements in Iliac Stent Technologies Driven by Product Innovation, Regulatory Approvals, and Clinical Evidence

Technological advanced product launch drives the growth of the market. For instance, in January 2025, Bentley InnoMed GmbH recently introduced its BeFlow covered iliac stent system, with commercial availability in Europe scheduled to begin in February 2025. As part of its rollout, the company plans to initiate a post-market clinical follow-up study under the leadership of Dr. Antonella Ruffino in Lugano, Switzerland. BeFlow, which holds CE Mark approval, is designed for managing both occlusive and stenotic disease in the iliac arteries. The system is offered in four diameter options ranging from 7 to 10 mm and two length configurations of 37 mm and 57 mm, enabling physicians to match device sizing to a broad range of lesion anatomies.

To learn more about this report, Download Free Sample Report

Moreover, in March 2025, Boston Scientific received FDA approval for its Express LD Iliac Premounted Stent System, authorizing its use specifically for the treatment of iliac artery disease. This makes the device the first low-profile, balloon-expandable, premounted stent cleared by the FDA for this indication. The company has confirmed that commercial availability in the U.S. will begin immediately. The Express LD Iliac Stent is built for enhanced deliverability, featuring the company’s Tandem Architecture, a design intended to optimize strength while maintaining flexibility and vessel conformity. Iliac artery disease, which results from atherosclerotic plaque restricting blood flow to the lower limbs, can cause significant leg discomfort and functional impairment. Management options vary from pharmacologic therapy to surgical bypass, with endovascular angioplasty and stenting serving as important minimally invasive alternatives.

Case Study Published by National Library of Medicine in January 2025- Short-Term Performance of a Balloon-Expandable Covered Stent in Iliac Artery Lesions

Overview- According to the NCBI article published in January 2025, a real-world cohort of 40 adult patients (87.5 % men; mean age ~63.5 ± 11 years) with atherosclerotic disease of the iliac arteries underwent endovascular treatment using the newly introduced iCover balloon-expandable covered stent.

• A total of 98 stents of various sizes were deployed across these patients.
• The procedure achieved technical success in 100% of cases.
• Over a mean follow-up period of 6.2 ± 2.8 months, the results were as follows:
  • Primary patency: 91.7% (95% CI: 89.8-93.6%)
  • Secondary patency: 95.8% (95% CI: 95%-96.6%)
  • Freedom from target-lesion revascularization (TLR): 95.8% at 6 months
  • All-cause mortality rate: 5% during the follow-up period.

Key takeaways

• A new balloon-expandable covered stent (iCover) showed high safety and efficacy in short-term follow-up in iliac artery disease.
• Very strong early patency rates and low re-intervention (TLR) rates indicate that premium covered stent technologies are performing well even in complex peripheral anatomy.
• The data supports the trend toward using covered, balloon-expandable stents in the iliac segment especially in scenarios needing high radial strength and controlled deployment.

Restraint: Procedural Complications and Clinical Risks Limiting Iliac Stent Adoption

The Iliac Stent market faces challenges due to the risk of procedural complications associated with endovascular implantation, including in-stent restenosis, thrombosis, stent fracture, and occlusion. Although advancements in stent design, drug-eluting technologies, and covered stents have significantly improved clinical outcomes, such complications can still occur, particularly in patients with severe calcification, long lesions, or chronic total occlusions. These risks may necessitate repeat interventions, increase long-term healthcare costs, and reduce physician confidence in certain complex cases. In addition, the need for highly skilled interventional expertise and advanced imaging support further limits procedural consistency across healthcare settings. For instance, in January 2025, a clinical study published on the NCBI database evaluating a balloon-expandable covered stent (iCover) for iliac artery lesions reported a 5% all-cause mortality rate and a requirement for close post-procedural monitoring despite high early technical success and favorable patency rates. The findings highlighted that while iliac stents demonstrate strong short-term efficacy, ongoing risks of complications and long-term management challenges remain relevant in real-world clinical practice.

Opportunity: Expansion of Advanced Endovascular Technologies and Next-Generation Iliac Stent Innovations

The integration of advanced stent technologies, including drug-eluting platforms, covered stents, and bioresorbable materials, presents a significant opportunity for the Iliac Stent market. These innovations are expected to enhance vascular healing, reduce restenosis rates, improve long-term patency, and enable more precise and minimally invasive treatment of complex iliac artery lesions. The growing use of digital health technologies, such as AI-assisted imaging, intravascular visualization, and data-driven procedural planning, is further improving procedural accuracy and clinical decision-making in endovascular interventions. These advancements are anticipated to expand the adoption of iliac stents across hospitals and specialized vascular centers. For instance, in March 2025, Boston Scientific received FDA approval for its Express LD Iliac Premounted Stent System, a low-profile, balloon-expandable stent designed specifically for iliac artery disease. The device incorporates advanced design features to enhance deliverability, flexibility, and vessel conformity, supporting improved procedural outcomes and expanding minimally invasive treatment options for peripheral artery disease patients.

Market Concentration & Characteristics

Technological advancements have supported new product development and aligned procedures with enhanced patency. According to an article published by the NCBI in February 2023, self-expanding covered stents provided exceptional results in the treatment of obstructive disease of the external iliac artery. Moreover, it was stated that < 8 mm-diameter stent reduces primary patency rates, with results portraying patency at 89.8% in 42 months.

To learn more about this report, Download Free Sample Report

The iliac stents market is characterized by a low level of M&A activities undertaken by leading players in the last three years. Several key companies undertook expansion measures in 2017 - 18 to gain entry into the iliac stents marketplace.

The iliac stents market is experiencing heightened regulatory scrutiny, with various regulatory and government authorities actively working to implement more rigorous guidelines. Stringent monitoring of the manufacturing process of iliac stents and post-marketing assessment by regulatory bodies, including the FDA, is likely to limit the market growth. For instance, in March 2022, the FDA issued a Class I product recall notice to Atrium Medical for its product, iCast Covered Stent, in the U.S. The product recall reason stated that the catheter hub separated from the delivery system, while the delivery system was removed from the person, causing fatal injuries or death.

Some of the key players in the market are focusing on introducing novel products that can cater to specific needs of patients. For instance, in August 2023, Suzhou Innomed Medical Device Co., Ltd. received approval from the China NMPA for its venous stent system indicated to be applied in the iliofemoral vein for treating non-thrombotic iliac vein compression.

Key companies in the iliac stents market are also focusing on market expansion. For instance, in November 2022, Medtronic, a key med-tech player, announced its expansionary plans in Costa Rica by allocating USD 65 million to launch a new manufacturing unit, completion of which is expected to finish by 2024.

Analyst Perspective

The market is benefiting from the rising prevalence of peripheral artery disease, atherosclerosis, and other vascular disorders that lead to iliac artery stenosis and occlusions. Increasing incidence of cardiovascular risk factors such as diabetes, hypertension, obesity, and smoking, along with the growing aging population, is significantly contributing to the burden of peripheral vascular diseases requiring endovascular intervention. Rising volumes of minimally invasive vascular procedures, including angioplasty and stent placement for iliac artery disease, are further supporting market expansion. Furthermore, advancements in stent technologies, including drug-eluting stents, covered stents, improved radial strength designs, and enhanced delivery systems, are improving procedural success rates, reducing restenosis, and driving broader adoption of iliac stents across hospitals, ambulatory surgical centers, and specialized vascular care facilities.

End-use Insights

Based on end use, the hospitals segment led the market with the largest revenue share of 61.6% in 2025. Hospitals are equipped with specialized facilities, such as cardiac catheterization labs and interventional radiology suites, where iliac stent placement is performed. According to NCBI, more than 300,000 procedures are performed in cardiac catheterization labs annually in the UK. Furthermore, patients with peripheral artery disease (PAD), including iliac artery occlusive disease, are often referred to hospitals by primary care physicians or specialists for further evaluation and treatment. Hospitals serve as referral centers where patients receive comprehensive care, including diagnostic imaging, medical management, and interventional procedures like iliac stent placement.

To learn more about this report, Download Free Sample Report

Outpatient facilities sector is projected to witness highest growth rate over the forecast period. Iliac stenting is performed using minimally invasive techniques such as percutaneous angioplasty and stenting, often necessitating local anesthesia and smaller incisions, which leads to reduced post-operative pain and shorter recovery time, which alleviates the procedure preference in ambulatory surgery centers or specialized clinics. Furthermore, outpatient stent placements are often cost-effective for both patients and healthcare providers compared to inpatient procedures performed in hospitals, which drives the segment demand. According to an article by Becker's Healthcare in September 2022, it was projected that by mid-2020s, ambulatory surgical centers will perform 33% of all cardiology procedures in the U.S., growing by nearly 23% from 2018.

Type Insights

Based on type, the self-expandable stents segment led the market with the largest revenue share of 60.7% in 2025. Self-expandable stents are designed to expand and hold open the narrowed or blocked iliac arteries, restoring proper blood flow to the lower extremities. This helps alleviate symptoms associated with iliac artery occlusive disease, such as leg pain, cramping, and numbness. Furthermore, self-expandable iliac stents are constructed from durable materials that help maintain the long-term patency of the treated artery. Furthermore, favorable long-term clinical study results are expected to instill confidence in healthcare providers.

Balloon-expandable stents segment is expected to witness considerable growth over forecast period. Balloon-expandable stents are positioned using angioplasty balloons, allowing for precise positioning and controlled expansion within the narrowed or blocked iliac artery. Furthermore, these stents are constructed from materials with high radial strength, such as stainless steel or cobalt-chromium alloys, which allow significant outward force against the arterial wall, effectively holding it open and resisting compression or collapse.

Artery Lesions Insights

Based on artery lesions, the common Iliac artery lesions segment led the market with the largest revenue share of 60.8% in 2025. Common iliac artery lesions are abnormalities or conditions that affect arteries that branch off from the aorta and supply blood to the pelvis and lower limbs. Some of the common iliac artery lesions are atherosclerosis, stenosis, occlusion, aneurysm, dissection, and others. The growing cases of patients suffering from high cholesterol and obesity are expected to boost the demand for iliac stents, as these conditions cause plaque buildup, which narrows or blocks artery lumen. According to an article published by the National Institutes of Health in March 2022, nearly half of the U.S. adults aged between 45 and 84 suffer from silent atherosclerosis.

The complete obstructive lesion segment is expected to witness considerable growth over the forecast period. This lesion refers to a total blockage or occlusion of the iliac artery caused by severe atherosclerosis or the formation of a blood clot (thrombus). Iliac stents are one of the primary treatment options for such lesions, as they can effectively reopen the blocked artery and maintain long-term patency. Furthermore, the growing fatality attributed to blood clots is expected to boost the demand for iliac stents. According to the National Blood Clot Alliance, nearly 274 people die each day from blood clots.

Regional Insights

North America dominated the Iliac Stent market with the largest revenue share of 43.8% in 2025. Growth in the region is driven by a high disease prevalence, rising consumer awareness, proactive government measures, technological advancements, and improvements in healthcare infrastructure. Moreover, presence of major companies involved in manufacturing iliac stents, such as Abbott, Medtronic, and W. L. Gore & Associates, is anticipated to drive market growth.

To learn more about this report, Download Free Sample Report

U.S. Iliac Stent Market Trends

The market in the U.S. held the largest share in the North America region in 2025. The increasing awareness about the disease, rising R&D for novel therapeutics, and growing prevalence of artery diseases are some of the key factors propelling market growth. According to the CDC, coronary artery disease accounts for 25% or 610,000 deaths annually in the U.S.

Europe Iliac Stent Market Trends

Europe's iliac stent market is the second largest market in 2025. Peripheral arterial disease (PAD) is one of the most common conditions in Europe. According to an article published by the NCBI in 2021 - 22, the prevalence of PAD was estimated at 17.8% in the population aged between 45 and 55. In addition, other multicenter studies from the Northern Europe region have stated that the prevalence of PAD was extremely high in the elderly.

The iliac stent market in the UK is estimated to grow at a significant CAGR over the forecast period. Demand for iliac stents in the UK continues to rise due to aging populations and increasing prevalence of peripheral artery disease. According to the Center for Ageing Better, nearly 19% or 11 million people in England were aged 65 and over. Technological advancements and favorable reimbursement policies are also driving market growth.

France iliac stent market is expected to grow over the forecast period. Growth is primarily driven by advancements in medical technology and a surge in vascular interventions. Increasing adoption of endovascular procedures and government initiatives also support market development. According to an article by the European Journal of Vascular & Endovascular Surgery in 2022, steady growth was seen in the French region for ambulatory endovascular revascularization procedures between 2015 & 2019, with authors projecting growth in the forthcoming years.

The iliac stent market in Germany held the largest share of the Europe market and is mainly driven by the growing preference for minimally invasive procedures. Furthermore, favorable healthcare infrastructure, enhanced insurance coverage, and rising awareness of peripheral artery disease contribute to market expansion. According to the IGES Institute, nearly 73.2 million Germans are covered by statutory health insurance. 

Asia Pacific Iliac Stent Market Trends

Asia Pacific iliac stent market is expected to grow at the fastest CAGR over the forecast period. Growing regulatory practices in third-world countries, increasing cardiovascular disease burden across growing economies such as India and China, and increasing geriatric population in developed countries are key factors driving the iliac stents market in this region.

The iliac stent market in China is estimated to grow at a significant CAGR over the forecast period. The changing regulatory framework is expected to propel product launches, positively impacting market growth. For instance, in January 2024, Zylox-Tonbridge Medical Technology Co., Ltd. received marketing approval from the National Medical Products Administration (NMPA) for its peripheral venous stent system.

Japan iliac stent market is expected to grow over the forecast period due to an increase in the geriatric population prone to peripheral diseases. Moreover, presence of key players such as Terumo Corporation is expected to drive growth in the country. However, factors such as the absence of national health insurance coverage for venous stenting and hindered macroeconomic activities are expected to restrain growth in the forecast period.

Latin America Iliac Stents Market Trends

The iliac stents market in Latin America is estimated to grow over the coming years owing to increasing government spending, the presence of skilled healthcare professionals, growing focus by multinational pharmaceutical companies on untapped markets, and rising patient awareness.

Brazil iliac stents market is expected to grow at a significant growth rate over the forecast period due to positive economic growth following financial and political stability in the country. In addition, the Brazilian government states the per capita healthcare spending to increase from USD 848 in 2020 to USD 1,165 in 2030.

MEA Iliac Stents Market Trends

The iliac stents market in MEA is growing due to the high economic development and improved healthcare facilities. Economic development and the presence of high unmet medical needs in emerging economies, such as South Africa, are primary factors driving market growth.

Saudi Arabia iliac stents market is expected to grow at a lucrative rate over the forecast period. High unmet clinical needs, rising disposable income, and increasing prevalence of peripheral artery disease (PAD) are expected to create opportunities for market growth in Saudi Arabia. According to an article by the MDPI in 2021 - 22, prevalence of PAD was estimated at 12% in the country.

Key Iliac Stent Company Insights

Some of the key established players operating in iliac stents market include Abbott, Boston Scientific Corporation, Medtronic, W. L. Gore & Associates, Inc., Terumo Corporation, and Cook. These companies are collaborating with regional players to expand their services geographically. iVascular, Limflow, and Vesper Medical are some of the emerging market participants in the iliac stents market. Emerging players focus more on collaborating with various research institutions to improve their clinical reach across the healthcare ecosystem.

Key Iliac Stent Companies

The following key companies have been profiled for this study on the iliac stents market.

• BD

• Abbott

• Boston Scientific Corporation

• W. L. Gore & Associates, Inc.

• Medtronic

• Cook

• Terumo Corporation

• iVascular

• Getinge AB

• Biotronik SE & Co KG

Recent Developments

• In February 2024, W.L. Gore & Associates, Inc. received approval from the U.S. FDA for its Viabahn VBX stent graft. The product offers enhanced strength as compared to bare metal stents in treating complex iliac occlusive disease.

• In October 2023, Getinge AB announced the commercial availability of its product, iCast covered stent system to treat iliac arterial occlusive disease in the U.S.

• In May 2022, iVascular announced the beginning of a trial for its latest product, the advanced covered stent named iCover. This product is designated for treating de novo aortoiliac lesions in individuals experiencing symptomatic arteriopathy of the lower limbs.

Global Iliac Stent Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global iliac stent market report based on type, artery lesions, end-use, and region. 

To learn more about this report, Download Free Sample Report

• Type Outlook (Revenue, USD Million, 2021 - 2033)

  • Self-expandable Stents

  • Balloon-expandable Stents

  • Others

• Artery Lesions Outlook (Revenue, USD Million, 2021 - 2033)

  • Common Iliac Artery Lesions

  • Severe Calcified Lesions

  • Complete Obstructive Lesions

• End-use Outlook (Revenue, USD Million, 2021 - 2033)

  • Hospitals

  • Outpatient Facilities

  • Others

• Regional Outlook (Revenue, USD Million, 2021 - 2033)

  • North America

    • U.S.

    • Canada

  • Europe

    • UK

    • Germany

    • France

    • Italy

    • Spain

    • Denmark

    • Sweden

    • Norway

  • Asia Pacific

    • Japan

    • China

    • India

    • South Korea

    • Australia

    • Thailand

  • Latin America

    • Brazil

    • Mexico

    • Argentina

  • Middle East and Africa (MEA)

    • South Africa

    • Saudi Arabia

    • UAE

    • Kuwait

Research Methodology

The iliac stent market figures in this report are based on a proven research process that combines executive interviews with secondary research from proprietary databases, company filings, and recognized regulatory and institutional sources. Market size is built through value-chain sizing - reconciling supply-side and demand-side estimates - and triangulated with bottom-up and top-down approaches. Every estimate passes multiple levels of expert validation before publication, with each iliac stent segment quantified using the revenue-capture definitions in the table below.

Estimation Model

The Iliac stents market has been analyzed using a multi-layered, procedure-based estimation framework that converts clinical intervention volumes into device unit demand and market revenue. The methodology reflects real-world endovascular treatment pathways while ensuring consistency across procedures, unit volumes, pricing, and market value.

The analytical framework combines multiple complementary models to ensure that market estimates are:

• Clinical representative

• Internally consistent across procedures, units, and revenue

• Validated against supply-side and commercial market dynamics

Model 1: Commodity Flow Analysis

Commodity flow analysis is used as a supply-side validation layer to verify procedure-derived unit demand and market value. The model compares estimated device demand with observable manufacturer revenues, product availability, commercial presence, procurement trends, and regional distribution patterns.

Key validation inputs include:

• Manufacturer revenue disclosures

• Product portfolio availability

• Regional commercial footprint

• Procurement and tender activity

• Distributor and shipment trends

Any deviation between modeled demand and commercial supply is investigated by refining clinical utilization assumptions, ensuring a transparent estimation process.

Model 2: Procedure Volume Modeling & Market Sizing Methodology

Procedure volume modeling forms the foundation of the Iliac Stent Market estimation.

Step 1: Procedure Universe Development

A comprehensive procedure database is established using:

• CPT codes

• ICD-10-PCS

• DRGs

• National registries

• Clinical guidelines

Duplicate coding and non-iliac interventions are excluded to develop a clean procedural universe.

Step 2: Iliac Stent Eligibility Assessment

Eligible interventions are identified by evaluating:

• Common iliac artery disease

• External iliac artery lesions

• Aortoiliac occlusive disease

• Iliac aneurysm repair

• Lesion complexity and treatment guidelines

Step 3: Product Type Allocation

Eligible procedures are allocated between balloon-expandable and self-expanding Iliac Stent using:

• Vessel anatomy

• Lesion characteristics

• Radial force requirements

• Physician preference

• Product indications

Step 4: Device Utilization Modeling

Procedure volumes are converted into unit demand by incorporating:

• Average stents per procedure

• Bilateral versus unilateral interventions

• Complex lesion treatment patterns

• Reintervention frequency

Step 5: Revenue Estimation

Unit volumes are multiplied by region-specific average selling prices (ASPs), considering:

• Product type

• Geographic pricing differences

• Tender versus commercial pricing

• Distributor pricing dynamics

CAGR Calculation & Validation

Forecast growth is developed using a bottom-up, segment-specific CAGR model.

Growth assumptions are independently estimated for each product type, application, and geography before being aggregated into regional and global forecasts.

Growth Drivers

• Increasing prevalence of peripheral artery disease

• Aging population

• Rising endovascular treatment adoption

• Expansion of minimally invasive vascular procedures

• Technological advancements in iliac stent platforms

• Improved reimbursement and hospital access

• Product innovation and competitive launches

Regional CAGRs are generated through weighted aggregation of individual segment forecasts and validated against:

• Historical procedure trends

• Regional adoption patterns

• Manufacturer commercial activity

• Pricing evolution

• Supply-side consistency

Delivered Customizations

This report has been delivered with the following In-depth customizations